CranioSense — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CranioSense is tackling a critical unmet need in neurology and emergency medicine: the non-invasive measurement of intracranial pressure (ICP). The current gold standard requires drilling into the skull, limiting its use to only the most critical 2% of TBI cases. The company's IPASS platform uses a forehead patch and clip-on sensors to provide a rapid ICP reading, potentially enabling earlier intervention for a vastly larger patient population. With clinical validation studies ongoing, CranioSense is positioned to disrupt the standard of care in neurocritical monitoring.

Traumatic Brain InjuryNeurology

Technology Platform

IPASS (Intracranial Pressure Assessment Screening System): A non-invasive platform using a forehead patch, clip-on sensors, and a handheld device to measure intracranial pressure (ICP) in seconds, likely based on pulse transit time (PTT) and proprietary algorithms.

Opportunities

The primary opportunity is to address the massive unmet need in the 98% of TBI patients who never receive ICP monitoring due to the risks of invasive procedures.

Successful commercialization would enable widespread screening in pre-hospital, emergency, and inpatient settings, potentially improving outcomes and reducing healthcare costs.

The platform could also be expanded to monitor other neurological conditions like stroke, hydrocephalus, and idiopathic intracranial hypertension.

Risk Factors

The major risk is technical/clinical: failing to achieve the required accuracy and reliability for clinical decision-making in rigorous, large-scale validation trials.

Significant regulatory hurdles exist for a novel diagnostic device, and securing favorable insurance reimbursement is a known challenge.

The company also faces competition from other groups developing non-invasive ICP solutions and must convince clinicians to adopt a new standard of care.

Competitive Landscape

The competitive landscape for non-invasive ICP monitoring is emerging but has no clear market leader yet. CranioSense competes against other early-stage companies and academic projects exploring methods like transcranial Doppler, tympanic membrane displacement, and optic nerve sheath diameter ultrasound. Its primary competition is the entrenched standard of care: invasive monitors from established medtech players like Integra LifeSciences and Raumedic, which are the current gold standard despite their limitations.

More companies in Diagnostics & Precision Medicine →More companies in United States →